var data={"title":"Mesna: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mesna: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6540?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mesna-drug-information\" class=\"drug drug_general\">see &quot;Mesna: Drug information&quot;</a> and <a href=\"topic.htm?path=mesna-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mesna: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193506\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mesnex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193507\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mesna for injection;</li>\n      <li>Uromitexan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048529\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cyclophosphamide-induced Hemorrhagic Cystitis</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Ifosfamide-induced Hemorrhagic Cystitis</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Chemoprotectant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048522\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mesna-drug-information\" class=\"drug drug_general\">see &quot;Mesna: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of ifosfamide-induced hemorrhagic cystitis:</b> Mesna dosing schedule should be repeated each day ifosfamide is received according to protocol. If ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio; Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Standard-dose ifosfamide: </i>\n      <b>Note:</b> ASCO defines standard-dose ifosfamide IV as &lt;2500 mg/m<sup>2</sup>/day (Hensley, 2009); other pediatric oncology experts suggest &le;2000 mg/m<sup>2</sup>/day in protocols. ASCO defines standard-dose ifosfamide oral as &le;2000 mg/m<sup>2</sup>/day (Hensley, 2009; Schuchter, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV: Mesna dose is equal to 20% of the ifosfamide dose given for 3 doses: With the ifosfamide dose (hour 0), at hour 4, and at hour 8 after the ifosfamide dose (total daily mesna dose is 60% of the ifosfamide dose). <b>Note:</b> Safety and efficacy not established for ifosfamide doses &gt;2000 mg/m<sup>2</sup>/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Short IV infusion (intermittent): ASCO guidelines: Mesna dose equal to 60% of the ifosfamide dose given in 3 divided doses (20% each) 15 minutes before the ifosfamide dose and at 4 and 8 hours after the start of ifosfamide (Hensley, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous IV infusion: Dosing regimens variable: ASCO guidelines: Mesna dose (as an IV bolus) equal to 20% of the ifosfamide dose, followed by a continuous IV infusion of mesna at 40% of the ifosfamide dose; continue mesna infusion for 12 to 24 hours after completion of ifosfamide infusion (Hensley, 2009). Some centers have used a mesna dose equal to 60% to 100% of the ifosfamide dose as a continuous IV infusion beginning 15 to 30 minutes before the first ifosfamide dose and completed at least 8 hours after the end of the ifosfamide infusion (Moskowitz, 2001). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: ASCO guidelines: Total mesna dose equal to 100% of the ifosfamide dose, begin with IV dose equal to 20% for initial dose followed by oral dose at 40% of the ifosfamide dose at 2 and 6 hours after start of ifosfamide (Hensley, 2009); <b>Note:</b> Typically, oral doses of mesna are twice the IV dose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-dose ifosfamide:</i> <b>Note:</b> ASCO defines high dose as ifosfamide dosage &ge;2500 mg/m<sup>2</sup>/day (Hensley, 2009); other pediatric oncology experts suggest &ge;2000 mg/m<sup>2</sup>/day in protocols: Limited data available; dosing regimens variable: IV: ASCO considers evidence for use inadequate and dosing recommendations are not established; more frequent and prolonged mesna administration regimens may be required (Hensley, 2009). Some centers have used a mesna dose equal to 100% of the ifosfamide dose as a short IV infusions 5 divided doses (0, 3, 6, 9 and 12) hours after the start of ifosfamide) (Kliegman, 2007) or as a continuous IV infusion beginning 15 to 30 minutes before the first ifosfamide dose and completed at least 12 hours after the end of the ifosfamide infusion. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other dosing strategies have been used in combination with ifosfamide for specific regimens/protocols:</i> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mesna continuous IV infusion: Children and Adolescents: IV: 1800 mg/m<sup>2</sup>/day to 5000 mg/m<sup>2</sup>/day as a continuous infusion (100% of the ifosfamide dose), repeated each day ifosfamide is received; see protocols for specific details (Bacci, 2003; Kolb, 2003; Moskowitz, 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mesna IV bolus followed by continuous IV infusion: Children and Adolescents: IV: 1000 mg/m<sup>2</sup> 1 hour prior to ifosfamide on day 1, followed by 3000 mg/m<sup>2</sup>/day continuous infusion (continuous infusion is 100% of the ifosfamide dose) on days 1, 2, and 3 (with sufficient hydration); administer with subsequent ifosfamide doses (Juergens, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mesna (20% higher than ifosfamide) continuous IV infusion: Children and Adolescents: IV: 3600 mg/m<sup>2</sup>/day continuous infusion for 4 days (mesna dose is 20% higher than ifosfamide), with hydration, administer with subsequent ifosfamide doses (Le Deley, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cyclophosphamide-induced hemorrhagic cystitis:</b> Limited data available: <b>Note:</b> Specific protocols should be consulted for combination regimens with cyclophosphamide. Mesna dosing schedule is typically repeated with each day cyclophosphamide is received; mesna dosing should be adjusted if cyclophosphamide dose is adjusted (decreased or increased) to maintain the mesna-to-cyclophosphamide ratio for the protocol; Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Standard (low)-dose cyclophosphamide:</i> <b>Note:</b> Some pediatric oncology experts have defined as cyclophosphamide dose &lt;1800 mg/m<sup>2</sup>/day in protocols. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> IV: Reported regimens variable: Mesna doses equivalent usually 60% to 100% of the cyclophosphamide daily dose although some protocols have used up to 160%. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Short IV infusion (intermittent): Mesna dose equal to 60% of the cyclophosphamide dose given in 3 divided doses (0, 4, and 8 hours after the start of cyclophosphamide) has been used by some centers; others have used a mesna dose equal to 100% of the cyclophosphamide dose as short IV infusions in 5 divided doses (0, 3, 6, 9, and 12 hours after the start of cyclophosphamide) (Kliegman, 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Some centers have used a mesna dose equal to 60% of the cyclophosphamide dose as a continuous IV infusion beginning 15 to 30 minutes before the first cyclophosphamide dose and completed at least 8 hours after the end of the cyclophosphamide infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Some centers have used a total mesna dose equal to 100% of the cyclophosphamide dose, begin with IV dose equal to 20% for initial dose followed by oral dose at 40% of the cyclophosphamide dose at 2 and 6 hours after start of cyclophosphamide; <b>Note:</b> Typically, oral doses of mesna are twice the IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>High-dose cyclophosphamide:</i>\n      <b> Note:</b> Some pediatric oncology experts have defined cyclophosphamide dose &ge;1800 mg/m<sup>2</sup>/day in protocols: IV: Some centers have used a mesna dose equal to 100% of the cyclophosphamide dose as short IV infusions in 5 divided doses (0, 3, 6, 9, and 12 hours after the start of) (Kliegman, 2007) or as a continuous IV infusion beginning 15 to 30 minutes before the first cyclophosphamide dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other dosing strategies have been used in combination with cyclophosphamide for specific regimens/protocols:</i> Limited data available: \tHDCAV/IE regimen for Ewing sarcoma: Children and Adolescents: IV: 2100 mg/m<sup>2</sup>/day continuous infusion (mesna dose is equivalent to the cyclophosphamide dose) \tfor 2 days with cyclophosphamide infusion during cycles 1, 2, 3, and 6 (Kolb, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Mesna dosing schedule should be repeated each day ifosfamide is received. If ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of ifosfamide-induced hemorrhagic cystitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Standard-dose ifosfamide</i> (manufacturer's labeling): IV: Mesna dose is equal to 20% of the ifosfamide dose given for 3 doses: With the ifosfamide dose, hour 4, and at hour 8 after of the ifosfamide dose (total daily mesna dose is 60% of the ifosfamide dose)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral mesna (following I.V mesna; for ifosfamide doses &le;2 g/m<sup>2</sup>/day): Mesna dose (IV) is equal to 20% of the ifosfamide dose at hour 0, followed by mesna dose (orally) equal to 40% of the ifosfamide dose given 2 and 6 hours after the ifosfamide dose (total daily mesna dose is 100% of the ifosfamide dose). <b>Note:</b> If the oral mesna dose is vomited within 2 hours of administration, repeat the dose or administer IV mesna.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Short infusion standard dose ifosfamide (&lt;2.5 g/m<sup>2</sup>/day): ASCO guidelines: IV: Total mesna dose is equal to 60% of the ifosfamide dose, in 3 divided doses (each mesna dose as 20% of ifosfamide dose), given 15 minutes before the ifosfamide dose, and 4 and 8 hours after each dose of ifosfamide (Hensley, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous infusion standard dose ifosfamide (&lt;2.5 g/m2/day): ASCO guidelines: IV: Mesna dose (as a bolus) is equal to 20% of the ifosfamide dose, followed by a continuous infusion of mesna at 40% of the ifosfamide dose; continue mesna infusion for 12 to 24 hours after completion of ifosfamide infusion (Hensley, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>High-dose ifosfamide</i> (&gt;2.5 g/m<sup>2</sup>/day): ASCO guidelines: Evidence for use is inadequate; more frequent and prolonged mesna administration regimens may be required (Hensley, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193483\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mesnex: 100 mg/mL (10 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mesnex: 400 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193469\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048533\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer orally in tablet form or dilute mesna injection solution for oral use before oral administration to decrease sulfur odor; see Extemporaneous Preparations section. Patients who vomit within 2 hours after taking oral mesna should repeat the dose or receive IV mesna.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer as an IV bolus (per manufacturer); current guidelines suggest administration by short IV infusion over 15 to 30 minutes, or by continuous IV infusion (maintain continuous infusion for 12 to 24 after completion of ifosfamide infusion) (Hensley 2009); in some trials, a shorter duration (eg, 8 hours) has been reported (Moskowitz 2001); refer to specific protocol for administration rate and details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193500\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials and tablets at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Opened multidose vials may be stored and used for use up to 8 days after initial puncture. Solutions diluted for infusion  in D5W, NS, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>3</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, or lactated Ringer's and stored at room temperature should be used within 24 hours. According to the manufacturer, mesna and ifosfamide may be mixed in the same bag if the final ifosfamide concentration is &le;50 mg/mL. Solutions of mesna and ifosfamide (1:1) in NS at a concentration of up to 20 mg/mL are stable for 14 days in PVC bags (Zhang, 2014). Solutions of mesna (0.5 to 3.2 mg/mL) and cyclophosphamide (1.8 to 10.8 mg/mL) in D5W are stable for 48 hours refrigerated or 6 hours at room temperature (Menard, 2003). Mesna injection prepared for oral administration is stable for at least 9 days undiluted in polypropylene syringes and stored at 5&deg;C, 24&deg;C, 35&deg;C; for 7 days when diluted 1:2 or 1:5 with syrups and stored at 24&deg;C in capped tubes; or for 24 hours at 5&deg;C when diluted to 1:2, 1:10, and 1:100 in orange or apple juice, milk, or carbonated beverages (Goren, 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048532\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Detoxifying agent used as a protectant against ifosfamide-induced hemorrhagic cystitis (Oral: FDA approved in adults; parenteral: FDA approved in pediatric patients [age not specified] and adults); has also been used as a protectant against cyclophosphamide-induced hemorrhagic cystitis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193556\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesna alone:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, headache, hyperesthesia, rigors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia (with oral administration), flatulence, nausea, unpleasant taste (with oral administration), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, flu-like symptoms, pharyngitis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening (mesna alone or in combination): Anaphylaxis, erythema at injection site, hypersensitivity reaction, hypertension, hypotension, increased serum transaminases, increased ST segment on ECG, limb pain, malaise, myalgia, pain at injection site, tachycardia, tachypnea, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193489\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mesna or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193473\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions have been reported; symptoms ranged from mild hypersensitivity to systemic anaphylactic reactions and may include fever, hypotension, tachycardia, acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, signs of disseminated intravascular coagulation, hematologic abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia. Reactions may occur with the first exposure, or after several months of treatment. Monitor for signs/symptoms of reactions. May require discontinuation. Patients with autoimmune disorders receiving cyclophosphamide and mesna may be at increased risk. Mesna is a thiol compound; it is unknown if the risk for reaction is increased in patients who have had a reaction to other thiol compounds (eg, amifostine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Drug rash with eosinophilia and systemic symptoms and bullous/ulcerative skin, and mucosal reactions consistent with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) have been reported. The skin and mucosal reactions  may be characterized by rash, pruritus, urticaria, erythema, burning sensation, angioedema, periorbital edema, flushing, and stomatitis. Reactions may occur with the first exposure, or after several months of treatment. May require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematuria: Monitor urine for hematuria. Severe hematuria despite utilization of mesna may require ifosfamide dose reduction or discontinuation. Examine morning urine specimen for hematuria prior to ifosfamide or cyclophosphamide treatment; if hematuria (&gt;50 RBC/HPF) develops, reduce the ifosfamide/cyclophosphamide dose or discontinue the drug; will not prevent hemorrhagic cystitis in all patients. Mesna will not reduce the risk of hematuria related to thrombocytopenia. Patients should receive adequate hydration during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ifosfamide/cyclophosphamide toxicities: Mesna is intended for the prevention of hemorrhagic cystitis and will not prevent or alleviate other toxicities associated with ifosfamide or cyclophosphamide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299676\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193476\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12585&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193479\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193492\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were not observed in animal reproduction studies. Use during pregnancy only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048528\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, urine color; monitor for hypersensitivity reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193472\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In blood, mesna is oxidized to dimesna which in turn is reduced in the kidney back to mesna, supplying a free thiol group which binds to and inactivates acrolein, the urotoxic metabolite of ifosfamide and cyclophosphamide</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193488\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 0.65 &plusmn; 0.24 L/kg; distributed to total body water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 69% to 75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly oxidized to mesna disulfide (dimesna) in the intravascular compartment. Mesna and dimesna do not undergo hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Free mesna: 58% (range: 45% to 71%); not affected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Mesna: ~22 minutes; Dimesna: ~70 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: Free mesna: 1.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (32% as mesna; 33% as dimesna); majority of IV dose excreted within 4 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048537\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">A preservative-free formulation of Mesnex injection may be obtained directly from the manufacturer. It is restricted for use in infants and children &lt;2 years and others who are sensitive to benzyl alcohol. Contact the manufacturer (Bristol-Meyers Squibb) for additional information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24888887\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">An oral solution may be prepared from mesna solution for injection. Dilute solution for injection to 20 mg/mL or 50 mg/mL with orange or grape syrup. Prior to administration, syrup-diluted solutions may be diluted to a final concentration of 1, 10, or 50 mg/mL with any of the following: Carbonated beverages, apple juice, orange juice, or milk. Mesna injection prepared for oral administration is stable for at least 9 days undiluted in polypropylene syringes and stored at 5&deg;C, 24&deg;C, 35&deg;C; for 7 days when diluted 1:2 or 1:5 with syrups and stored at 24&deg;C in capped tubes; or for 24 hours at 5&deg;C when diluted to 1:2, 1:10, and 1:100 in orange or apple juice, milk, or carbonated beverages. Dilution of mesna with diet or sugar-free preparations has not been evaluated.</p>\n    <div class=\"reference\">Goren MP, Lyman BA, Li JT. The stability of mesna in beverages and syrup for oral administration. <i>Cancer Chemother Pharmacol</i>. 1991;28(4):298-301.<span class=\"pubmed-id\">1908750</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323377\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mesna Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $39.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mesnex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $39.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mesnex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (10): $943.09</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193493\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Delinar (AR);</li>\n      <li>Ifomes (BD);</li>\n      <li>Mescryo (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Mesnil (MX, PE, PY);</li>\n      <li>Mesodal (MX);</li>\n      <li>Mistabron (KR, LU, PH, VN);</li>\n      <li>Mitexan (BR);</li>\n      <li>Mucofluid (ES);</li>\n      <li>Novacarel (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Uromes (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Uromiteksan (UA);</li>\n      <li>Uromitexan (AE, AT, AU, BE, BG, BH, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IN, IS, IT, JO, KR, KW, LB, LT, LU, MT, NL, NO, NZ, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VN);</li>\n      <li>Uroprot (MX, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. <i>Ann Oncol</i>. 2003;14(7):1126-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12853357/pubmed\" target=\"_blank\" id=\"12853357\">12853357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goren MP, Lyman BA, Li JT. The stability of mesna in beverages and syrup for oral administration. <i>Cancer Chemother Pharmacol</i>. 1991;28(4):298-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/1908750/pubmed\" target=\"_blank\" id=\"1908750\">1908750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hensley ML, Hagerty KL, Kewalramani T, et al, &quot;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants,&quot;<i> J Clin Oncol</i>, 2009, 27(1):127-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/19018081/pubmed\" target=\"_blank\" id=\"19018081\">19018081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. <i>Pediatr Blood Cancer</i>. 2006;47(1):22-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/16572419/pubmed\" target=\"_blank\" id=\"16572419\">16572419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khaw SL, Downie PA, Waters KD, et al, &quot;Adverse Hypersensitivity Reactions to Mesna as Adjunctive Therapy for Cyclophosphamide,&quot; <i>Pediatr Blood Cancer</i>, 2007, 49(3):341-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/16333822/pubmed\" target=\"_blank\" id=\"16333822\">16333822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. <i>J Clin Oncol</i>. 2003;21(18):3423-3430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12972518/pubmed\" target=\"_blank\" id=\"12972518\">12972518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. <i>Eur J Cancer</i>. 2007;43(4):752-761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/17267204/pubmed\" target=\"_blank\" id=\"17267204\">17267204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menard C, Bourguignon C, Schlatter J, et al, &quot;Stability of Cyclophosphamide and Mesna Admixtures in Polyethylene Infusion Bags,&quot; <i>Ann Pharmacother</i>, 2003, 37(12):1789-92.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mesnex (mesna) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i>. 2001;97(3):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/11157476/pubmed\" target=\"_blank\" id=\"11157476\">11157476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schoenike SE and Dana WJ, &ldquo;Ifosfamide and Mesna,&rdquo; <i>Clin Pharm</i>, 1990, 9(3):179-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/2107997/pubmed\" target=\"_blank\" id=\"2107997\">2107997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuchter LM, Hensley ML, Meropol NJ, et al, &quot;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&quot; <i>J Clin Oncol</i>, 2002, 20(12):2895-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12065567/pubmed\" target=\"_blank\" id=\"12065567\">12065567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang Y, Kawedia JD, Myers AL, et al. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. <i>J Oncol Pharm Pract</i>. 2014;20(1):51-57. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/23512269/pubmed\" target=\"_blank\" id=\"23512269\">23512269</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12585 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193506\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193507\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048529\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048522\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193483\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F193469\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048533\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F193500\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048532\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193556\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193489\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193473\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299676\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193476\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193479\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F193492\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048528\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193472\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F193488\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1048537\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F24888887\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323377\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193493\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12585|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mesna-drug-information\" class=\"drug drug_general\">Mesna: Drug information</a></li><li><a href=\"topic.htm?path=mesna-patient-drug-information\" class=\"drug drug_patient\">Mesna: Patient drug information</a></li></ul></div></div>","javascript":null}